

Ref. No: FOI1403  
Date: 12/12/2024  
Subject: Asthma

## REQUEST

**Q1. How many patients have been treated (for any condition) in the last 4 months with:**

- Benralizumab
- Dupilumab
- Omalizumab
- Reslizumab
- Mepolizumab
- Tezepelumab

**Q2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:**

- Age 6-11
- Age 12-17
- Age 18 and above

**Q3. How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with:**

- Dupilumab
- Omalizumab

**Q4. How many patients have been diagnosed with BOTH chronic sinusitis (ICD-10 code J32) AND nasal polyps (ICD-10 code J33) in the past year? Of these patients, how many have been treated in the last 4 months with:**

- Benralizumab
- Dupilumab
- Omalizumab
- Reslizumab
- Mepolizumab
- Tezepelumab

## RESPONSE

**Q1. How many patients have been treated (for any condition) in the last 4 months with:**

- Benralizumab - 0
- Dupilumab - 132
- Omalizumab - 30
- Reslizumab - 0
- Mepolizumab - 0
- Tezepelumab - 0

**Q2. Of the patients treated in the last 4 months with any of the above products, please provide the number of patients by the following age-groups:**

- Age 6-11 - 0
- Age 12-17 - 6
- Age 18 and above - 156

**Q3. How many patients have been treated in the last 4 months by the Respiratory Medicine department ONLY with:**

- Dupilumab - 0
- Omalizumab - 6

**Q4. How many patients have been diagnosed with BOTH chronic sinusitis (ICD-10 code J32) AND nasal polyps (ICD-10 code J33) in the past year? Of these patients, how many have been treated in the last 4 months with:**

Unable to answer as we do not hold information about specific indications.